Home arrow Health arrow hnews arrow New approach to "re-sensitize" treatment resistant tumours Friday, 21 November 2008
 
 
   
Google
 
 
HomeWorldFinanceSci/TechHealthEntertainmentSportsContact Us

New approach to "re-sensitize" treatment resistant tumours Print E-mail
Tag it:
Delicious
Furl it!
Spurl
NewsVine
Reddit
YahooMyWeb
Technorati
Wists
YahooMyWeb
Blinkbits
BlinkList
blogmarks
co.mments
connotea
Digg
Stumble
User Rating: / 0
PoorBest 
Written by ANI   
Saturday, 06 September 2008

Washington, Sept 6 (ANI): Researchers from Georgetown University Medical Centre have suggested a new approach that can "re-sensitize" tumours, which have become resistant to treatment, thus allowing anti-hormonal drugs to do their job once again.

The study focussed on breast cancers that are fuelled by estrogen-these are called estrogen-receptor or progesterone-receptor positive cancers (ER or PR positive).

Women who have ER or PR positive metastatic breast cancer often take anti-hormonal medicines, such as aromatase inhibitors to slow down cancer progression, however, cancer becomes resistant to this approach and begins to grow.

"At first, the tumour's growth is halted because the aromatase inhibitor is depriving the cancer of the estrogen it needs to grow," said Claudine Isaacs, M.D., clinical director of breast cancer program at Georgetown University Medical Centre's Lombardi Comprehensive Cancer Centre.

"Eventually, though, the cancer will figure out another way to thrive in the absence of the estrogen," she added.

The research team led Isaacs including Indian origin lead author Deepa Subramaniam, M.D. of Lombardi, are conducting a clinical trial to see if a new approach can destroy the machinery the tumour creates in order to grow without the estrogen. The drug being studied is called sorafenib.

The preliminary results have shown clinical benefit response in 26 percent of the patients taking both sorafenib and anastrozole.

"Given what we know about the ineffectiveness of sorafenib alone in metastatic breast cancer, we believe the benefit that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," said Isaacs.

"To manage breast cancer long term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach. In a sense, for each step back, we hope to take two steps forward," she added.

The study was presented at the ASCO 2008 Breast Cancer Symposium. (ANI)


Add as favourites (12)

Be first to comment this article
RSS comments

Write Comment
  • Please keep the topic of messages relevant to the subject of the article.
  • Personal verbal attacks will be deleted.
  • Please don't use comments to plug your web site. Such material will be removed.
  • Just ensure to *Refresh* your browser for a new security code to be displayed prior to clicking on the 'Send' button.
  • Keep in mind that the above process only applies if you simply entered the wrong security code.
Name:
E-mail
BBCode:Web AddressEmail AddressBold TextItalic TextUnderlined TextQuoteCodeOpen ListList ItemClose List
Comment:



Code:* Code
I wish to be contacted by email regarding additional comments

Powered by AkoComment Tweaked Special Edition v.1.4.4

Last Updated ( Saturday, 06 September 2008 )
 
< Prev   Next >

Intimacy Linked to Lower Stres...
What we should do?
More...

Intimacy Linked to Lower Stres...
New Study! What is new about it? All couples will tell you t...
More...

Freddie Mac did pay millions t...
The third and last U.S. Presidential Debate took place in He...
More...

Nutritionist Reveals 20 Functi...
very ggod.
More...

Nutritionist Reveals 20 Functi...
Healthy food leads to healthy lifestyle
More...

 
About Us | Privacy Policy | Advertise | Contact Us
©2007-2008 NewsLocale.org, All Rights Reserved